My clinical practice includes general urology with a focus on female urology, male voiding dysfunction and neurogenic bladder. I am located at the Buffalo General Medical Center. I trained in Buffalo for residency and then had an opportunity to do a fellowship under Dr. David Ginsberg at the University of Southern California. Our focus included male and female incontinence and voiding dysfunction, pelvic organ prolapse, recurrent urinary tract infections, fistulae and neurogenic bladder. My experience at USC as well as Rancho Los Amigos National Rehabilitation Center allowed me to work with spinal cord injured patients, Spina Bifida, stroke, multiple sclerosis, Parkinson‘s disease and other various neurologic disorders. My research interests include long-term outcomes of neurogenic bladder management, the use of botulinum toxin in the management of neurogenic bladder and its effects on long-term treatment and outcomes of treatment of pelvic organ prolapse.
My urology clinical practice at the Veteran‘s Administration Western New York Healthcare System in Buffalo, NY is a high volume variety of cases of general urology and urologic oncology, ranking from minor procedures to complex major cancer cases. Being fellowship trained at the Roswell Park Cancer Institute, my special interests are urologic oncology and robotic and laparoscopic surgeries. My research interests are prostate and bladder cancer.
Dr. Mohler earned his medical degree from the Medical College of Georgia and completed residency training in Surgery and Urology at the University of Kentucky Medical Center and a research fellowship in Urologic Oncology at The Johns Hopkins University School of Medicine. Dr. Mohler is licensed by New York and North Carolina, a Diplomate of the National Board of Medical Examiners and the American Board of Urology, and a Fellow of the American College of Surgeons. Dr. Mohler is Chair of the NCCN Prostate Cancer Guideline Committee, Past-President of the Society for Basic Urologic Research and Vice-Chair of the Urology Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB) and is a member of the American Medical Association, American Association for the Advancement of Science, American Association for Cancer Research, American Urological Association and American College of Surgeons. He is a 2015 Distinguished Scholar Alumnus of the American Urological Association. Dr. Mohler’s clinical practice focuses upon prostate cancer and robot-assisted laparoscopic surgery. His laboratory focuses upon the role of the androgen receptor in racial differences in prostate cancer aggressiveness and prostate cancer recurrence during androgen deprivation therapy. He has authored or co-authored more than 200 publications and book chapters, and a book “Androgen Action in Prostate Cancer.” He serves on the editorial board of The Prostate, Journal of the National Comprehensive Cancer Network, Journal of Robotic Surgery, and Therapeutic Advances in Urology, and reviews for several journals including Cancer, Cancer Research, Clinical Cancer Research, Journal of Molecular Endocrinology, Journal of Urology, Oncogene, Science Translational Medicine and Urology.
Research interests include interdisciplinary studies in neurourology and urinary incontinence. These studies involve rehabilitation of the patient with spinal cord injury, particularly as relates to the urinary tract and the treatment of incontinence, particularly in geriatric patients. I am also interested in female urology and in particular, mechanisms and strategies of female urinary control and its treatment. Finally, new approaches to the treatment of reconstruction of the lower urinary tract in general, and in reconstruction of bladder function in particular are other areas of research interests.
My research interests in general are in urologic oncology and in specific prostate and renal malignancy. Research interests are primarily clinical research and translational research. We are presently investigating novel therapies in the treatment of prostatic malignancy. The effect of early diagnosis and therapy on long term survival is also under investigation, as is the use of neoadjuvant therapy. In addition, I am active in national urologic research planning and strategies serving as a member of a National Institute of Health Study Section (NIDDK) and as chair of the research committee of the American Urological Association. In the latter capacity regular meetings are held with representatives of the various institutes of the National Institutes of Health.